638 related articles for article (PubMed ID: 22015634)
1. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
3. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S; Sole S
Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967
[TBL] [Abstract][Full Text] [Related]
4. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
[TBL] [Abstract][Full Text] [Related]
7. 16,17-Dihydro-17b-hydroxy isomitraphylline alkaloid as an inhibitor of DPP-IV, and its effect on incretin hormone and β-cell proliferation in diabetic rat.
Shukla A; Srinivasan BP
Eur J Pharm Sci; 2012 Sep; 47(2):512-9. PubMed ID: 22820565
[TBL] [Abstract][Full Text] [Related]
8. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
9. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
Akarte AS; Srinivasan BP; Gandhi S
Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Burkey BF; Li X; Bolognese L; Balkan B; Mone M; Russell M; Hughes TE; Wang PR
J Pharmacol Exp Ther; 2005 Nov; 315(2):688-95. PubMed ID: 16027230
[TBL] [Abstract][Full Text] [Related]
11. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
12. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
14. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
[TBL] [Abstract][Full Text] [Related]
15. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Bianchi R; Cervellini I; Porretta-Serapiglia C; Oggioni N; Burkey B; Ghezzi P; Cavaletti G; Lauria G
J Pharmacol Exp Ther; 2012 Jan; 340(1):64-72. PubMed ID: 21984837
[TBL] [Abstract][Full Text] [Related]
17. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
19. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
20. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Jin HY; Liu WJ; Park JH; Baek HS; Park TS
Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]